bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Table 1 from Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Authors: Schoenfeld Adam J. , Chan Joseph M. , Kubota Daisuke , Sato Hiroki , Rizvi Hira , Daneshbod Yahya , Chang Jason C. , Paik Paul K. , Offin Michael , Arcila Maria E. , Davare Monika A. , Shinde Ujwal , Pe'er Dana , Rekhtman Natasha , Kris Mark G. , Somwar Romel , Riely Gregory J. , Ladanyi Marc , Yu Helena A.
Published: April 2023

Supplemental Table 1. MET amplification
Supplemental Figure 2 from Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Authors: Schoenfeld Adam J. , Chan Joseph M. , Kubota Daisuke , Sato Hiroki , Rizvi Hira , Daneshbod Yahya , Chang Jason C. , Paik Paul K. , Offin Michael , Arcila Maria E. , Davare Monika A. , Shinde Ujwal , Pe'er Dana , Rekhtman Natasha , Kris Mark G. , Somwar Romel , Riely Gregory J. , Ladanyi Marc , Yu Helena A.
Published: April 2023

Supplemental Figure 2. Contextual landscape of resistance to osimertinib by line of therapy and type of alteration.
Table S3 from Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Authors: Awasthi Shivanshu , Berglund Anders , Abraham-Miranda Julieta , Rounbehler Robert J. , Kensler Kevin , Serna Amparo , Vidal Adriana , You Sungyong , Freeman Michael R. , Davicioni Elai , Liu Yang , Karnes R. Jeffrey , Klein Eric A. , Den Robert B. , Trock Bruce J. , Campbell Joshua D. , Einstein David J. , Gupta Raavi , Balk Steven , Lal Priti , Park Jong Y. , Cleveland John L. , Rebbeck Timothy R. , Freedland Stephen J. , Yamoah Kosj
Published: April 2023

Table S3
Tables from Characterizing CDK12-Mutated Prostate Cancers
Authors: Rescigno Pasquale , Gurel Bora , Pereira Rita , Crespo Mateus , Rekowski Jan , Rediti Mattia , Barrero Maialen , Mateo Joaquin , Bianchini Diletta , Messina Carlo , Fenor de la Maza Maria D. , Chandran Khobe , Carmichael Juliet , Guo Christina , Paschalis Alec , Sharp Adam , Seed George , Figueiredo Ines , Lambros Maryou , Miranda Susana , Ferreira Ana , Bertan Claudia , Riisnaes Ruth , Porta Nuria , Yuan Wei , Carreira Suzanne , de Bono Johann S.
Published: April 2023

Supplemental tables
Supplemental Figures from Characterizing CDK12-Mutated Prostate Cancers
Authors: Rescigno Pasquale , Gurel Bora , Pereira Rita , Crespo Mateus , Rekowski Jan , Rediti Mattia , Barrero Maialen , Mateo Joaquin , Bianchini Diletta , Messina Carlo , Fenor de la Maza Maria D. , Chandran Khobe , Carmichael Juliet , Guo Christina , Paschalis Alec , Sharp Adam , Seed George , Figueiredo Ines , Lambros Maryou , Miranda Susana , Ferreira Ana , Bertan Claudia , Riisnaes Ruth , Porta Nuria , Yuan Wei , Carreira Suzanne , de Bono Johann S.
Published: April 2023

Supplemental Figures
Immunochemistry of CEACAM7 expression on PDAC from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma
Authors: Raj Deepak , Nikolaidi Maria , Garces Irene , Lorizio Daniela , Castro Natalia M. , Caiafa Sabrina G. , Moore Kate , Brown Nicholas F. , Kocher Hemant M. , Duan Xiaobo , Nelson Brad H. , Lemoine Nicholas R. , Marshall John F.
Published: April 2023

Immunochemistry of CEACAM7 expression on PDAC
Expression of CEACAM7 on c76 cultures from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma
Authors: Raj Deepak , Nikolaidi Maria , Garces Irene , Lorizio Daniela , Castro Natalia M. , Caiafa Sabrina G. , Moore Kate , Brown Nicholas F. , Kocher Hemant M. , Duan Xiaobo , Nelson Brad H. , Lemoine Nicholas R. , Marshall John F.
Published: April 2023

Expression of CEACAM7 on c76 cultures
CEACAM7 expression on PDX lines using flow cytometry from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma
Authors: Raj Deepak , Nikolaidi Maria , Garces Irene , Lorizio Daniela , Castro Natalia M. , Caiafa Sabrina G. , Moore Kate , Brown Nicholas F. , Kocher Hemant M. , Duan Xiaobo , Nelson Brad H. , Lemoine Nicholas R. , Marshall John F.
Published: April 2023

CEACAM7 expression on PDX lines using flow cytometry
Supplementary Data from Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial
Authors: Stenmark Tullberg Axel , Puttonen Henri A.J. , Sjöström Martin , Holmberg Erik , Chang S. Laura , Feng Felix Y. , Speers Corey , Pierce Lori J. , Lundstedt Dan , Killander Fredrika , Niméus Emma , Kovács Anikó , Karlsson Per
Published: April 2023

Supplement
Analysis of CAR T-cells transduced or untransduced with 2869 from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma
Authors: Raj Deepak , Nikolaidi Maria , Garces Irene , Lorizio Daniela , Castro Natalia M. , Caiafa Sabrina G. , Moore Kate , Brown Nicholas F. , Kocher Hemant M. , Duan Xiaobo , Nelson Brad H. , Lemoine Nicholas R. , Marshall John F.
Published: April 2023

Analysis of CAR T-cells transduced or untransduced with 2869 CAR
Supplementary Data from Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial
Authors: Stenmark Tullberg Axel , Puttonen Henri A.J. , Sjöström Martin , Holmberg Erik , Chang S. Laura , Feng Felix Y. , Speers Corey , Pierce Lori J. , Lundstedt Dan , Killander Fredrika , Niméus Emma , Kovács Anikó , Karlsson Per
Published: April 2023

Study protocol
Supplementary Table-9 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Validation samples misclassified by 472-gene wSVM classifier: Gold standard CMS, predicted CMS, the class probabilities pij for each CMS (probability for gold standard in bold), and maximum probability aI for validation samples (V1ap) misclassified by 472-gene wSVM
Supplementary Table-8 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Comparison of Classifiers. Comparison of random forest (RF) and single sample predictors (SSP) in Guinney et al. (2015) paper with our wSVM classifier with 472 genes, either forcing a single CMS call for each sample (all calls) or only when classified with high confidence
eTable3 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Univariate and multivariate analysis of high TMB {greater than or equal to}7 and {greater than or equal to}10 mutations/Mb and PTEN alterations with progression-free and overall survival following chemotherapy
Supplementary Data from Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
Authors: Isomoto Kohsuke , Haratani Koji , Hayashi Hidetoshi , Shimizu Shigeki , Tomida Shuta , Niwa Takashi , Yokoyama Toshihide , Fukuda Yasushi , Chiba Yasutaka , Kato Ryoji , Tanizaki Junko , Tanaka Kaoru , Takeda Masayuki , Ogura Takashi , Ishida Tadashi , Ito Akihiko , Nakagawa Kazuhiko
Published: April 2023

Supplementary_Figures
eFigure3 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Kaplan-Meier Curves for Progression-Free Survival and Overall Survival by high TMB {greater than or equal to}7 mutations/Mb and PTEN alterations in Chemotherapy-Treated mTNBC. (A) Progression-free survival and (C) overall survival by tumor mutational burden <7 vs. {greater than or equal to}7 mutations/megabase; (B) Progression-free survival and (D) overall survival by PTEN alteration (absent vs. present).
eFigure2 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Tumor mutational burden in known PD-L1-positive and negative tumors (n = 37)
Supplementary Methods and Results from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Extended methods and results, including e-references
Supplementary Figure S8 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure S8. The waterfall plots of the best percentage change in the tumor burden from baseline evaluation in patients treated with CAPTEM (left panels) and FOLFIRI (right panels) according to MGMT IHC expression and MGMT % methylation by Methyl-BEAMing.
Table S4 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Frequencies of genomic alterations between three datasets.
Figure S1 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Patient age distribution within each liquid biopsy dataset depicted as a boxplot of median and IQR inside a violin plot.
Supplementary Data from Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
Authors: Wang Chunmeng , Liu Yang , Dong Liang , Li Xiang , Yang Qingming , Brock Malcolm V. , Mei Qian , Liu Jiejie , Chen Meixia , Shi Fengxia , Liu Miao , Nie Jing , Han Weidong
Published: April 2023

Supplementary Data
Figure S5 from A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Authors: Karn Thomas , Meissner Tobias , Weber Karsten E. , Solbach Christine , Denkert Carsten , Engels Knut , Fasching Peter A. , Sinn Bruno V. , Schrader Iris , Budczies Jan , Marmé Frederik , Müller Volkmar , Holtrich Uwe , Gerber Bernd , Schem Christian , Young Brandon M. , Hanusch Claus , Stickeler Elmar , Huober Jens , van Mackelenbergh Marion , Leyland-Jones Brian , Fehm Tanja , Nekljudova Valentina , Untch Michael , Loibl Sibylle
Published: April 2023

Comparison of gene signature detection in High Quality and Low Quality Samples
Table S3 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Oligonucleotides used in this study
Table S2 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Recombinant antibodies
Figure S9 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Co-stimulatory activity of control antibodies.
Figure S8 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Effect of 4-1BBN/CEGFR trimerbody on EGFR-mediated signaling
Figure S6 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Species specificity of the 4-1BBN/CEGFR trimerbody.
Supplementary Video 1 from A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
Authors: Santich Brian H. , Cheal Sarah M. , Ahmed Mahiuddin , McDevitt Michael R. , Ouerfelli Ouathek , Yang Guangbin , Veach Darren R. , Fung Edward K. , Patel Mitesh , Burnes Vargas Daniela , Malik Aiza A. , Guo Hong-Fen , Zanzonico Pat B. , Monette Sebastien , Michel Adam O. , Rudin Charles M. , Larson Steven M. , Cheung Nai K.
Published: April 2023

2-step SADA-PRIT imaging by PET/CT
Figure S13 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Representative images of CD3+ and FoxP3+ TIL immunostaining
Figure S3 from A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
Authors: Santich Brian H. , Cheal Sarah M. , Ahmed Mahiuddin , McDevitt Michael R. , Ouerfelli Ouathek , Yang Guangbin , Veach Darren R. , Fung Edward K. , Patel Mitesh , Burnes Vargas Daniela , Malik Aiza A. , Guo Hong-Fen , Zanzonico Pat B. , Monette Sebastien , Michel Adam O. , Rudin Charles M. , Larson Steven M. , Cheung Nai K.
Published: April 2023

summary of toxicity data from 177Lu SADA-PRIT experiment against a neuroblastoma PDX
Figure S10 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Co-stimulation studies in primary human cells
Supplemental Data from Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers
Authors: Tsang Erica S. , Grisdale Cameron J. , Pleasance Erin , Topham James T. , Mungall Karen , Reisle Caralyn , Choo Caleb , Carreira Marcus , Bowlby Reanne , Karasinska Joanna M. , MacMillan Daniel , Williamson Laura M. , Chuah Eric , Moore Richard A. , Mungall Andrew J. , Zhao Yongjun , Tessier-Cloutier Basile , Ng Tony , Sun Sophie , Lim Howard J. , Schaeffer David F. , Renouf Daniel J. , Yip Stephen , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Loree Jonathan M.
Published: April 2023

Supplemental Data
Supplementary Data from Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Authors: Zhou Caicun , Wang Yina , Zhao Jun , Chen Gongyan , Liu Zhihua , Gu Kangsheng , Huang Meijuan , He Jianxing , Chen Jianhua , Ma Zhiyong , Feng Jifeng , Shi Jianhua , Yu Xinmin , Cheng Ying , Yao Yu , Chen Yuan , Guo Renhua , Lin Xiaoyan , Wang Zhehai , Gao Guanghui , Wang Quanren , Li Weixia , Yang Xinfeng , Wu Lihong , Zhang Jun , Ren Shengxiang
Published: April 2023

Supplementary figures and tables
Supplementary Methods from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Authors: Jhaveri Komal , Chang Matthew T. , Juric Dejan , Saura Cristina , Gambardella Valentina , Melnyk Anton , Patel Manish R. , Ribrag Vincent , Ma Cynthia X. , Aljumaily Raid , Bedard Philippe L. , Sachdev Jasgit C. , Dunn Lara , Won Helen , Bond John , Jones Surai , Savage Heidi M. , Scaltriti Maurizio , Wilson Timothy R. , Wei Michael C. , Hyman David M.
Published: April 2023

Supplementary Methods
Supplementary Figure 5 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Authors: Collins Denis M. , Madden Stephen F. , Gaynor Nicola , AlSultan Dalal , Le Gal Marion , Eustace Alex J. , Gately Kathy A. , Hughes Clare , Davies Anthony M. , Mahgoub Thamir , Ballot Jo , Toomey Sinead , O'Connor Darran P. , Gallagher William M. , Holmes Frankie A. , Espina Virginia , Liotta Lance , Hennessy Bryan T. , O'Byrne Kenneth J. , Hasmann Max , Bossenmaier Birgit , O'Donovan Norma , Crown John
Published: April 2023

All ADCC ratios from Figure 3 and trastuzumab/pertuzumab ADCC comparison
Supplementary Methods from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
Authors: Kalbasi Anusha , Kamrava Mitchell , Chu Fang-I , Telesca Donatello , Van Dams Ritchell , Yang Yingli , Ruan Dan , Nelson Scott D. , Dry Sarah M. , Hernandez Jackie , Chmielowski Bartosz , Singh Arun S. , Bukata Susan V. , Bernthal Nicholas M. , Steinberg Michael L. , Weidhaas Joanne B. , Eilber Fritz C.
Published: April 2023

Supplementary Methods
Supplementary Figure S4 from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
Authors: Kalbasi Anusha , Kamrava Mitchell , Chu Fang-I , Telesca Donatello , Van Dams Ritchell , Yang Yingli , Ruan Dan , Nelson Scott D. , Dry Sarah M. , Hernandez Jackie , Chmielowski Bartosz , Singh Arun S. , Bukata Susan V. , Bernthal Nicholas M. , Steinberg Michael L. , Weidhaas Joanne B. , Eilber Fritz C.
Published: April 2023

Figure S4 - Characteristics of major wound complications.
Supplementary Figure 4 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Authors: Collins Denis M. , Madden Stephen F. , Gaynor Nicola , AlSultan Dalal , Le Gal Marion , Eustace Alex J. , Gately Kathy A. , Hughes Clare , Davies Anthony M. , Mahgoub Thamir , Ballot Jo , Toomey Sinead , O'Connor Darran P. , Gallagher William M. , Holmes Frankie A. , Espina Virginia , Liotta Lance , Hennessy Bryan T. , O'Byrne Kenneth J. , Hasmann Max , Bossenmaier Birgit , O'Donovan Norma , Crown John
Published: April 2023

Densitometry for Figure 2B
Supplementary Figure S1 from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
Authors: Kalbasi Anusha , Kamrava Mitchell , Chu Fang-I , Telesca Donatello , Van Dams Ritchell , Yang Yingli , Ruan Dan , Nelson Scott D. , Dry Sarah M. , Hernandez Jackie , Chmielowski Bartosz , Singh Arun S. , Bukata Susan V. , Bernthal Nicholas M. , Steinberg Michael L. , Weidhaas Joanne B. , Eilber Fritz C.
Published: April 2023

Figure S1 - CONSORT diagram.
Supplementary Figure Legends from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
Authors: Kalbasi Anusha , Kamrava Mitchell , Chu Fang-I , Telesca Donatello , Van Dams Ritchell , Yang Yingli , Ruan Dan , Nelson Scott D. , Dry Sarah M. , Hernandez Jackie , Chmielowski Bartosz , Singh Arun S. , Bukata Susan V. , Bernthal Nicholas M. , Steinberg Michael L. , Weidhaas Joanne B. , Eilber Fritz C.
Published: April 2023

Supplementary Figure Legends
Supplementary figure 1 from Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
Authors: Wolska-Kusnierz Beata , Pastorczak Agata , Fendler Wojciech , Wakulinska Anna , Dembowska-Baginska Bozena , Heropolitanska-Pliszka Edyta , Piątosa Barbara , Pietrucha Barbara , Kałwak Krzysztof , Ussowicz Marek , Pieczonka Anna , Drabko Katarzyna , Lejman Monika , Koltan Sylwia , Gozdzik Jolanta , Styczynski Jan , Fedorova Alina , Miakova Natalia , Deripapa Elena , Kostyuchenko Larysa , Krenova Zdenka , Hlavackova Eva , Gennery Andrew R. , Sykora Karl-Walter , Ghosh Sujal , Albert Michael H. , Balashov Dmitry , Eapen Mary , Svec Peter , Seidel Markus G. , Kilic Sara S. , Tomaszewska Agnieszka , Wiesik-Szewczyk Ewa , Kreins Alexandra , Greil Johann , Buechner Jochen , Lund Bendik , Gregorek Hanna , Chrzanowska Krystyna , Mlynarski Wojciech
Published: April 2023

The dynamics of primary cancer incidence among patients with NBS described using the three-stage joint-point model.
Table S2 from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers
Authors: Zhang Hongyi , Liu Longchao , Zhang Jian , Chen Jiahui , Ye Jianfeng , Shukla Sachet , Qiao Jian , Zhan Xiaowei , Chen Hao , Wu Catherine J. , Fu Yang-Xin , Li Bo
Published: April 2023

Three common HLA alleles predicted by NetMHC with strong binding affinities to a HSFX1 derived 9-mer peptide (HSFX1: 384-392).
Supplementary Figures from Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers
Authors: Zhang Hongyi , Liu Longchao , Zhang Jian , Chen Jiahui , Ye Jianfeng , Shukla Sachet , Qiao Jian , Zhan Xiaowei , Chen Hao , Wu Catherine J. , Fu Yang-Xin , Li Bo
Published: April 2023

Figure S1-13. Figure S1. Performance evaluation for iSMART, TCRdist and GLIPH. Figure S2. Cluster antigen-specificity analysis for iSMART, TCRdist and GLIPH. Figure S3. Summary of iSMART identified CDR3 clusters. Figure S4. Clustered CDR3s as an indicator for activated T cells Figure S5. Differentially expressed gene analysis for the tissue resident memory subpopulations. Figure S6. Additional tSNE plot visualization for selected markers. Figure S7. Mitochondrial gene fraction in different T cell subpopulations. Figure S8. Pseudotime trajectory plots for individual clonotypes in sample BC10. Figure S9. Single cell trajectory analysis for breast cancer sample BC11. Figure S10. HSFX1 expression across cancer types and normal tissues. Figure S11. Generation of a potentially immunogenic peptide by HSFX1 expression. Figure S12. Immunospot assays for HSFX1-derived peptide using naïve C57BL/6J mice and immunohistochemistry staining of HSFX1 in normal human tissues. Figure S13. TSSK2 expression across human cancers.
Supplementary Figure 2 from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
Authors: Rahma Osama E. , Reuss Joshua E. , Giobbie-Hurder Anita , Shoja E Razavi Ghazaleh , Abu-Shawer Osama , Mehra Pooja , Gupta Seema , Simon Richard , Khleif Samir N.
Published: April 2023

Supplementary Figure 2
Supplemental Figure 1 from Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Authors: Choudhury Noura J. , Schoenfeld Adam J. , Flynn Jessica , Falcon Christina J. , Rizvi Hira , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Heller Glenn , Yu Helena A. , Ladanyi Marc , Riely Gregory J.
Published: April 2023

Patient details
Supplementary Data from OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Authors: Gutierrez Martin , Moreno Victor , Heinhuis Kimberley M. , Olszanski Anthony J. , Spreafico Anna , Ong Michael , Chu Quincy , Carvajal Richard D. , Trigo José , Ochoa de Olza Maria , Provencio Mariano , De Vos Filip Yves , De Braud Filippo , Leong Stephen , Lathers Deanne , Wang Rui , Ravindran Palani , Feng Yan , Aanur Praveen , Melero Ignacio
Published: April 2023

Supplementary figures and text
Supplementary Figure S3 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Authors: Pachynski Russell K. , Kim Eric H. , Miheecheva Natalia , Kotlov Nikita , Ramachandran Akshaya , Postovalova Ekaterina , Galkin Ilia , Svekolkin Viktor , Lyu Yang , Zou Qiong , Cao Dengfeng , Gaut Joseph , Ippolito Joseph E. , Bagaev Alexander , Bruttan Maria , Gancharova Olga , Nomie Krystle , Tsiper Maria , Andriole Gerald L. , Ataullakhanov Ravshan , Hsieh James J.
Published: April 2023

Supplementary Figure S3. Immune cell populations present in the epithelium and stroma of mpMRI-invisible and -visible PCa. A, Box plots showing the percentage of specific immune cell subsets in the different compartments of mpMRI-invisible and -visible PCa tumors. B, Box plots showing the percentage of stromal cells in the different compartments of relapsed or non-relapsed PCa tumors.
Supplementary Figure S2 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer
Authors: Pachynski Russell K. , Kim Eric H. , Miheecheva Natalia , Kotlov Nikita , Ramachandran Akshaya , Postovalova Ekaterina , Galkin Ilia , Svekolkin Viktor , Lyu Yang , Zou Qiong , Cao Dengfeng , Gaut Joseph , Ippolito Joseph E. , Bagaev Alexander , Bruttan Maria , Gancharova Olga , Nomie Krystle , Tsiper Maria , Andriole Gerald L. , Ataullakhanov Ravshan , Hsieh James J.
Published: April 2023

Supplementary Figure S2. The mpMRI-visible PCa tumors show marked differences between the malignant and non-malignant compartments. A, Box plots showing WD per mpMRI-invisible and -visible PCa tumors. P-values were calculated with the Mann-Whitney U test. B, Combination of WD plotted against the malignant cell density per mpMRI-visible and -invisible PCa tumors and patient relapse.
Supplementary Table 1 from Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial
Authors: Vidal Joana , Casadevall David , Bellosillo Beatriz , Pericay Carles , Garcia-Carbonero Rocio , Losa Ferran , Layos Laia , Alonso Vicente , Capdevila Jaume , Gallego Javier , Vera Ruth , Salud Antonieta , Martin-Richard Marta , Nogué Miguel , Cillán Elena , Maurel Joan , Faull Iris , Raymond Victoria , Fernández-Martos Carlos , Montagut Clara
Published: April 2023

Baseline clinico-pathological characteristics from patients included versus not included in the ctDNA analysis
Supplementary Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Authors: van den Ende Tom , de Clercq Nicolien C. , van Berge Henegouwen Mark I. , Gisbertz Suzanne S. , Geijsen E.D. , Verhoeven R.H.A. , Meijer Sybren L. , Schokker Sandor , Dings M.P.G. , Bergman Jacques J.G.H.M. , Haj Mohammad Nadia , Ruurda Jelle P. , van Hillegersberg Richard , Mook Stella , Nieuwdorp Max , de Gruijl Tanja D. , Soeratram Tanya T.D. , Ylstra Bauke , van Grieken Nicole C.T. , Bijlsma Maarten F. , Hulshof Maarten C.C.M. , van Laarhoven H.W.M.
Published: April 2023

Figure S1. Trial design of the PERFECT study.
Supplementary Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Authors: van den Ende Tom , de Clercq Nicolien C. , van Berge Henegouwen Mark I. , Gisbertz Suzanne S. , Geijsen E.D. , Verhoeven R.H.A. , Meijer Sybren L. , Schokker Sandor , Dings M.P.G. , Bergman Jacques J.G.H.M. , Haj Mohammad Nadia , Ruurda Jelle P. , van Hillegersberg Richard , Mook Stella , Nieuwdorp Max , de Gruijl Tanja D. , Soeratram Tanya T.D. , Ylstra Bauke , van Grieken Nicole C.T. , Bijlsma Maarten F. , Hulshof Maarten C.C.M. , van Laarhoven H.W.M.
Published: April 2023

Figure S2. Flowchart of patients included in the PERFECT trial.
Supplementary Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Authors: van den Ende Tom , de Clercq Nicolien C. , van Berge Henegouwen Mark I. , Gisbertz Suzanne S. , Geijsen E.D. , Verhoeven R.H.A. , Meijer Sybren L. , Schokker Sandor , Dings M.P.G. , Bergman Jacques J.G.H.M. , Haj Mohammad Nadia , Ruurda Jelle P. , van Hillegersberg Richard , Mook Stella , Nieuwdorp Max , de Gruijl Tanja D. , Soeratram Tanya T.D. , Ylstra Bauke , van Grieken Nicole C.T. , Bijlsma Maarten F. , Hulshof Maarten C.C.M. , van Laarhoven H.W.M.
Published: April 2023

Supplementary Methods
Supplementary Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
Authors: van den Ende Tom , de Clercq Nicolien C. , van Berge Henegouwen Mark I. , Gisbertz Suzanne S. , Geijsen E.D. , Verhoeven R.H.A. , Meijer Sybren L. , Schokker Sandor , Dings M.P.G. , Bergman Jacques J.G.H.M. , Haj Mohammad Nadia , Ruurda Jelle P. , van Hillegersberg Richard , Mook Stella , Nieuwdorp Max , de Gruijl Tanja D. , Soeratram Tanya T.D. , Ylstra Bauke , van Grieken Nicole C.T. , Bijlsma Maarten F. , Hulshof Maarten C.C.M. , van Laarhoven H.W.M.
Published: April 2023

Table S1. Combined positivity score (CPS) in responders and non-responders at baseline. Table S2. Immunohistochemistry markers evaluated at baseline and on-treatment.
Supplementary Figure SF3 from Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma
Authors: Seidlitz Annekatrin , Beuthien-Baumann Bettina , Löck Steffen , Jentsch Christina , Platzek Ivan , Zöphel Klaus , Linge Annett , Kotzerke Jörg , Petr Jan , van den Hoff Jörg , Steinbach Jörg , Krex Dietmar , Schmitz-Schackert Gabriele , Falk Monique , Baumann Michael , Krause Mechthild
Published: April 2023

suppl. figure SF3
Supplementary Figure SF2 from Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma
Authors: Seidlitz Annekatrin , Beuthien-Baumann Bettina , Löck Steffen , Jentsch Christina , Platzek Ivan , Zöphel Klaus , Linge Annett , Kotzerke Jörg , Petr Jan , van den Hoff Jörg , Steinbach Jörg , Krex Dietmar , Schmitz-Schackert Gabriele , Falk Monique , Baumann Michael , Krause Mechthild
Published: April 2023

suppl. figure SF2
Supplementary Data from Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma
Authors: Seidlitz Annekatrin , Beuthien-Baumann Bettina , Löck Steffen , Jentsch Christina , Platzek Ivan , Zöphel Klaus , Linge Annett , Kotzerke Jörg , Petr Jan , van den Hoff Jörg , Steinbach Jörg , Krex Dietmar , Schmitz-Schackert Gabriele , Falk Monique , Baumann Michael , Krause Mechthild
Published: April 2023

suppl. table 1-4
Supplementary figure from MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions
Authors: Sato Hiroki , Schoenfeld Adam J. , Siau Evan , Lu Yue Christine , Tai Huichun , Suzawa Ken , Kubota Daisuke , Lui Allan J.W. , Qeriqi Besnik , Mattar Marissa , Offin Michael , Sakaguchi Masakiyo , Toyooka Shinichi , Drilon Alexander , Rosen Neal X. , Kris Mark G. , Solit David , De Stanchina Elisa , Davare Monika A. , Riely Gregory J. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary figures are included.
Supplementary Data S1-2 from Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma
Authors: Seidlitz Annekatrin , Beuthien-Baumann Bettina , Löck Steffen , Jentsch Christina , Platzek Ivan , Zöphel Klaus , Linge Annett , Kotzerke Jörg , Petr Jan , van den Hoff Jörg , Steinbach Jörg , Krex Dietmar , Schmitz-Schackert Gabriele , Falk Monique , Baumann Michael , Krause Mechthild
Published: April 2023

suppl. data S1-2
Supplementary Table S2 from Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Authors: Kiyokawa Juri , Kawamura Yoichiro , Ghouse Shanawaz M. , Acar Simge , Barçın Erinç , Martínez-Quintanilla Jordi , Martuza Robert L. , Alemany Ramon , Rabkin Samuel D. , Shah Khalid , Wakimoto Hiroaki
Published: April 2023

Supplementary Table S2
Supplementary Tables 1-11 from ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma
Authors: Myojin Yuta , Kodama Takahiro , Maesaka Kazuki , Motooka Daisuke , Sato Yu , Tanaka Satoshi , Abe Yuichi , Ohkawa Kazuyoshi , Mita Eiji , Hayashi Yoshito , Hikita Hayato , Sakamori Ryotaro , Tatsumi Tomohide , Taguchi Ayumu , Eguchi Hidetoshi , Takehara Tetsuo
Published: April 2023

Supplementary Tables 1-11
Supplementary Figures from Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Authors: Kiyokawa Juri , Kawamura Yoichiro , Ghouse Shanawaz M. , Acar Simge , Barçın Erinç , Martínez-Quintanilla Jordi , Martuza Robert L. , Alemany Ramon , Rabkin Samuel D. , Shah Khalid , Wakimoto Hiroaki
Published: April 2023

Supplementary Figures 1-9
Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Authors: Wick Antje , Bähr Oliver , Schuler Martin , Rohrberg Kristoffer , Chawla Sant P. , Janku Filip , Schiff David , Heinemann Volker , Narita Yoshitaka , Lenz Heinz-Josef , Ikeda Masafumi , Ando Yuichi , Wick Wolfgang , Steinbach Joachim P. , Burger Michael C. , Wenger Katharina , Lassen Ulrik , Sankhala Kamalesh K. , Roggia Cristiana , Genvresse Isabelle , Munhoz Catya , Rentzsch Christine , Reschke Susanne , Langer Simon , Wagner Markus , Kaulfuss Stefan , Cai Charles , Lagkadinou Eleni , Jeffers Michael , Peña Carol , Tabatabai Ghazaleh
Published: April 2023

Supplementary Figure S4. Exposure-response analysis of Cmax on C1-D1 vs. best response in LGG subjects.
Table S1 from Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Authors: Graillon Thomas , Sanson Marc , Campello Chantal , Idbaih Ahmed , Peyre Matthieu , Peyrière Hadrien , Basset Noémie , Autran Didier , Roche Catherine , Kalamarides Michel , Roche Pierre-Hugues , Fuentes Stéphane , Tabouret Emeline , Barrie Maryline , Cohen Anita , Honoré Stéphane , Boucekine Mohamed , Baumstarck Karine , Figarella-Branger Dominique , Barlier Anne , Dufour Henry , Chinot Olivier Louis
Published: April 2023

Table S1: Patient characteristics T : Tumor ; IK : Karnofski index; NA : Not available, SST2 : SST2 receptor expression (IRS Immunoreactivity score ) ; Conv: Convexity; RT: Radiotherapy; RS: Radiosurgery; CT chemotherapy * : for the NF2 genomic alterations, deletion and mutation of the gene were researched according to the quality of the available tumoral fragment(cf Table S4)
Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Authors: Wick Antje , Bähr Oliver , Schuler Martin , Rohrberg Kristoffer , Chawla Sant P. , Janku Filip , Schiff David , Heinemann Volker , Narita Yoshitaka , Lenz Heinz-Josef , Ikeda Masafumi , Ando Yuichi , Wick Wolfgang , Steinbach Joachim P. , Burger Michael C. , Wenger Katharina , Lassen Ulrik , Sankhala Kamalesh K. , Roggia Cristiana , Genvresse Isabelle , Munhoz Catya , Rentzsch Christine , Reschke Susanne , Langer Simon , Wagner Markus , Kaulfuss Stefan , Cai Charles , Lagkadinou Eleni , Jeffers Michael , Peña Carol , Tabatabai Ghazaleh
Published: April 2023

Supplementary Methods, Supplementary Results, Supplementary Tables S1-S11
Table S1, Table S1B, Table S2 from Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312)
Authors: Cole Kristina A. , Pal Sharmistha , Kudgus Rachel A. , Ijaz Heba , Liu Xiaowei , Minard Charles G. , Pawel Bruce R. , Maris John M. , Haas-Kogan Daphne A. , Voss Stephan D. , Berg Stacey L. , Reid Joel M. , Fox Elizabeth , Weigel Brenda J.
Published: April 2023

S1. Patient Characteristics of eligible (n=37) and MTD/RP2D evaluable (n=27) patients S1B. Diagnosis of eligible (n=37) and MTD/RP2D evaluable (n=27) patients. S2. In Cycle 1, All Hematologic and Non-Hematologic toxicities related to protocol therapy in evaluable patients (N=27)
Supplementary Figure 3 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Authors: Davids Matthew S. , Kuss Bryone J. , Hillmen Peter , Montillo Marco , Moreno Carol , Essell James , Lamanna Nicole , Nagy Zsolt , Tam Constantine S. , Stilgenbauer Stephan , Ghia Paolo , Delgado Julio , Lustgarten Stephanie , Weaver David T. , Youssoufian Hagop , Jäger Ulrich
Published: April 2023

Figure S3 displays probability of overall survival over time in the study population
Supplementary Table S1 from In Vivo Tracking of Adoptively Transferred Natural Killer Cells in Rhesus Macaques Using 89Zirconium-Oxine Cell Labeling and PET Imaging
Authors: Sato Noriko , Stringaris Kate , Davidson-Moncada Jan K. , Reger Robert , Adler Stephen S. , Dunbar Cynthia , Choyke Peter L. , Childs Richard W.
Published: April 2023

Zr-89 oxine labeled cell doses infused to rhesus macaques.
Supplementary Data from Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Authors: Petrylak Daniel P. , Loriot Yohann , Shaffer David R. , Braiteh Fadi , Powderly John , Harshman Lauren C. , Conkling Paul , Delord Jean-Pierre , Gordon Michael , Kim Joseph W. , Sarkar Indrani , Yuen Kobe , Kadel Edward E. , Mariathasan Sanjeev , O'Hear Carol , Narayanan Sujata , Fassò Marcella , Carroll Susheela , Powles Thomas
Published: April 2023

Supplement
Supplementary Data 4 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
Authors: Li Yingming , Yang Rendong , Henzler Christine M. , Ho Yeung , Passow Courtney , Auch Benjamin , Carreira Suzanne , Nava Rodrigues Daniel , Bertan Claudia , Hwang Tae Hyun , Quigley David A. , Dang Ha X. , Morrissey Colm , Fraser Michael , Plymate Stephen R. , Maher Christopher A. , Feng Felix Y. , de Bono Johann S. , Dehm Scott M.
Published: April 2023

AR Gene Rearrangement Calls in AR-Targeted Cohort
Figure S7 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Authors: Vázquez-Borrego Mari C. , Gupta Vandana , Ibáñez-Costa Alejandro , Gahete Manuel D. , Venegas-Moreno Eva , Toledano-Delgado Álvaro , Cano David A. , Blanco-Acevedo Cristóbal , Ortega-Salas Rosa , Japón Miguel A. , Barrera-Martín Ana , Vasiljevic Alexandre , Hill Jason , Zhang Shengwen , Halem Heather , Solivera Juan , Raverot Gérald , Gálvez María A. , Soto-Moreno Alfonso , Paez-Pereda Marcelo , Culler Michael D. , Castaño Justo P. , Luque Raúl M.
Published: April 2023

Intracellular signaling involved in the effects observed in response to SST3- agonists.
Figure S6 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Authors: Vázquez-Borrego Mari C. , Gupta Vandana , Ibáñez-Costa Alejandro , Gahete Manuel D. , Venegas-Moreno Eva , Toledano-Delgado Álvaro , Cano David A. , Blanco-Acevedo Cristóbal , Ortega-Salas Rosa , Japón Miguel A. , Barrera-Martín Ana , Vasiljevic Alexandre , Hill Jason , Zhang Shengwen , Halem Heather , Solivera Juan , Raverot Gérald , Gálvez María A. , Soto-Moreno Alfonso , Paez-Pereda Marcelo , Culler Michael D. , Castaño Justo P. , Luque Raúl M.
Published: April 2023

Representative immunohistochemical staining (400X magnification; scale bar: 20μm) for SST3 measured in responsive and unresponsive NFPAs.
Figure S1 from A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Authors: Vázquez-Borrego Mari C. , Gupta Vandana , Ibáñez-Costa Alejandro , Gahete Manuel D. , Venegas-Moreno Eva , Toledano-Delgado Álvaro , Cano David A. , Blanco-Acevedo Cristóbal , Ortega-Salas Rosa , Japón Miguel A. , Barrera-Martín Ana , Vasiljevic Alexandre , Hill Jason , Zhang Shengwen , Halem Heather , Solivera Juan , Raverot Gérald , Gálvez María A. , Soto-Moreno Alfonso , Paez-Pereda Marcelo , Culler Michael D. , Castaño Justo P. , Luque Raúl M.
Published: April 2023

Validation by qPCR of SSTR3 gene silencing with two specific siRNAs using the BON-1 cell line.
Figure S5 from PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Authors: Shaffer Travis , Natarajan Arutselvan , Gambhir Sanjiv S.
Published: April 2023

Supplementary Figure 5. A) A representative immunofluorescences figure illustrates the homing of the TILs in melanoma.
Figure S4 from PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Authors: Shaffer Travis , Natarajan Arutselvan , Gambhir Sanjiv S.
Published: April 2023

Supplementary Figure 4. A) 64Cu-TIGITAb (red dotted line) iTLC shows a pure product, with free 64Cu (green solid line) is shown for comparison. B) 89Zr-TIGITAb (red dotted line) iTLC shows a pure product, with free 89Zr (green solid line) is shown for comparison. C) SE HPLC shows UV-Vis abs (280 nm, red line) and radio-signal (blue dotted line) at the same retention time, demonstrating the intact TIGITAb was successfully radiolabeled with 64Cu
Figure S2 from PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Authors: Shaffer Travis , Natarajan Arutselvan , Gambhir Sanjiv S.
Published: April 2023

Supplementary Figure 2. HeLa cells stably expressing the mouse TIGIT receptor and eGFP.
Table S2 from Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
Authors: Paoletti Costanza , Barlow William E. , Cobain Erin F. , Bergqvist Mattias , Mehta Rita S. , Gralow Julie R. , Hortobagyi Gabriel N. , Albain Kathy S. , Pusztai Lajos , Sharma Priyanka , Godwin Andrew K. , Thompson Alastair M. , Hayes Daniel F. , Rae James M.
Published: April 2023

Supplementary Table 2. Multivariable Model of sTKI after Adjustment for Treatment, Age, and Disease Characteristics.